Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

NCT01459796 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT01459796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01459796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2011
Completion date
June 30, 2013
Enrollment
220 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

gout